Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors (ONCO AESTHETIC)
Improved Facial Skin Quality After Intradermal Injection of a Cross-linked 12mg/ml Hyaluronic Acid (VYC-12L) and Its Impact on Self-perception and Quality of Life in Patients With a Prior History of Breast Cancer Who Have Received and Completed Treatment With Chemotherapy and/or Systemic Monoclonal Antibodies.
Systemic treatments such as chemotherapy or monoclonal antibodies are an essential part of oncological treatment in breast cancer, which have demonstrated a survival benefit (1,2,3,4,5). This cancer is the most common cancer in women, being the cancer with the highest incidence worldwide (6), with an estimated 35,001 new cases in 2023 in Spain (7). This is why a large number of patients receive systemic treatments that help surgery and radiotherapy to achieve a cure of over 80% in our environment, with a 5-year overall survival of 85.5% having been described (7).
These systemic oncological treatments generate well-known skin alterations such as xerosis, pruritus, erythema, pigmentation alterations, papulo-pustular eruptions, dermatosis, and others such as psoriasis (8,9,10,11).
The multimodal treatment of cancer finally becomes a long and hard process which, added to the fear of the diagnosis itself, and the physical changes as a consequence of these treatments, end up reducing the state of mind of the patients who suffer from it (12,13,14).
Self-care and the aesthetic improvement of the patient's appearance are the main reasons for this.
There are aesthetic treatments, such as hyaluronic acid 12mg/ml cross-linked (VYC-12L) in intradermal injection, that could improve the quality and aesthetics of the facial skin, which could help to improve the self-perception of patients who receive it, helping them to recover their self-confidence and improve their quality of life.
Research Question:
To objectively compare the skin quality of patients with previous history of breast cancer who have received and completed treatment with chemotherapy and/or monoclonal antibodies, before and after intradermal injection a cross-linked hyaluronic acid 12mg/ml (VYC-12L) in addition to self-esteem and quality of life.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Antonio J Lozano, Doctor
- 電話番号：+34 ES 626980234
- メール：antoniojlozano@live.com
研究場所
-
-
Murcia
-
Murcia、Murcia、スペイン、30120
- 募集
- Ctra.Madrid-Cartagena, s/n, El Palmar
-
コンタクト：
- Antonio J Lozano, Doctor
- 電話番号：+34 ES-626980234
- メール：antoniojlozano@live.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with previous clinical history of having received and completed oncological treatment with chemotherapy and/or systemic monoclonal antibodies for breast cancer in the previous 1-18 months will be included.
説明
Inclusion Criteria:
- Patients over 18 years old of age.
- Patients with a previous clinical history of having had breast cancer, who have received treatment and finished with chemotherapy and/or systemic monoclonal antibodies between the previous 1-18 months.
- Patients who have received and completed treatment with neoadjuvant or adjuvant chemotherapy and/or monoclonal antibodies to breast cancer surgery between 1-18 months prior to recruitment.
- Patients who, in the physician's opinion, can understand and properly answer study questionnaires.
- Patients to whom participation in this study was offered and they voluntarily decided to join and signed the informed consent.
Exclusion Criteria:
- Patients suffering from untreated epilepsy.
- Patients with a tendency to develop hypertrophic scars.
- Patients with known hypersensitivity to hyaluronic acid and/or gram-positive bacterial proteins since hyaluronic acid is produced by Streptococcus type bacteria.
- Patients with known hypersensitivity to lidocaine or amide-type local anesthetics.
- Patients suffering from porphyria.
- Pregnant or lactating women.
- Patients presenting inflammatory and/or infectious processes (acne, herpes, etc.).
- Patients should not be subjected to laser treatments, deep chemical peels or dermabrasion during the duration of the study.
- Patients with no history of psychiatric illnesses derived from the oncologic diagnosis such as confirmed major depression.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Intervention
intradermal injection |
12mg/ml cross-linked hyaluronic acid (VYC-12L) will be applied, distributed in 1 to 2 ml per side of the face in intradermal injection. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Skin Hydration and Elasticity From Baseline
時間枠：Before the treatment and at 4 and 24 weeks after the initial treatment
|
To assess the improvement compared to baseline on the hydration and elasticity using a Multidermascope Microcaya MDS 1000 skin analyzer device. Scale of 0 to 99, higher scores mean a better outcome. |
Before the treatment and at 4 and 24 weeks after the initial treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Skin quality based on investigator and subject assessments compared to baseline
時間枠：At baseline, and on week 4 and 24 post study treatment
|
To assess the aesthetic improvement on skin quality based on investigator and subject assessments compared to baseline through an analysis with the VISIA device with 2D and 3D images at baseline using the FACE-Q Aesthetics - Psychological Function Scale . Scale of 0 to 100, higher scores mean a better outcome. |
At baseline, and on week 4 and 24 post study treatment
|
|
Change in Self-Esteem From Baseline
時間枠：At baseline, and on week 4 and 24 post study treatment
|
To assess the overall improvement on self-esteem based on subjects assessments using the Rosemberg questionnaire (Rosenberg Self - Esteem Scale) at baseline. Scale of 0 to 40, higher scores mean a better outcome. |
At baseline, and on week 4 and 24 post study treatment
|
|
Change in Quality of Life From Baseline
時間枠：At baseline, and on week 4 and 24 post study treatment
|
To assess the overall improvement on the quality of life based on subjects assessments using the EORTC QLQ-BR23 questionnaire quality of life specific to this patient population. Scale of 0 to 100, higher scores mean a better outcome. |
At baseline, and on week 4 and 24 post study treatment
|
|
Global Aesthetic Improvement Based on GAIS Assessment
時間枠：At week 4 and 24 post study treatment
|
To assess an overall aesthetic improvement based on investigator and subject assessments of at least a one-point improvement on the Global Aesthetic Improvement Scale (GAIS). Scale of 1 to 5, higher scores mean a worse outcome. |
At week 4 and 24 post study treatment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。